OKYO Pharma Limited announced promising results from a Phase 2 clinical trial of urcosimod, a treatment for neuropathic corneal pain (NCP), where 75% of patients receiving 0.05% urcosimod reported ...
Nasdaq: OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain ("NCP")
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain ("NCP")
Seeking Alpha: OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
Nasdaq: OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain ("NCP") Following Announcement of Clinical Trial Agreement with Tufts Medical Center
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain ("NCP") Following Announcement of Clinical Trial Agreement with Tufts Medical Center
Business Insider: OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod (previously referred to as OK-101), aimed at treating neuropathic corneal pain (NCP). The ...
In this video, James explains how to use the NCPMobile app to redeem NCP reward points for gift cards, sweepstakes prizes and more.
NCP launched a new panel member website recently! Learn more about the new website's home page and how to find what you're looking for.